BioCrine
  • Home
  • About Us
    • Company and People
    • Board of Directors
    • Management
    • Partners
  • Research Programs
    • Pipeline overview
    • Diabetes as a disease
    • Biocrine drug discovery strategy
    • Serum factor apoCIII
    • Insulin receptor isoforms
    • Calcium channels
    • Inositol pyrophosphates
  • InSight Technology
    • What is it?
    • How does it work?
    • Where can it be used?
  • News
  • Contact
Home » News » Publication » The pancreatic islet as a signaling hub

The pancreatic islet as a signaling hub

The researchers in Professor Berggren’s group are in the forefront of resolving key challenges in understanding the molecular signalling in the islets of Langerhans, the endocrine pancreas. Specification of differences between human and mouse islet architecture and function as well as possibility to image molecular processes in the living organism will eventually lead to insights into how to treat diabetes. 

Over the last two decades researchers in Prof Berggren’s group have brought many new insights into signal-transduction within the insulin-producing beta cell. The majority of the discoveries were however made under conditions, where the cells were separated from their natural environment. Alongside that, there has been a growing awareness that the beta cells are to a large extend influenced by the unique environment of the islet of Langerhans. There, beta cells receive signals from other cells, such as for instance glucagon releasing alpha cells and endothelial cells from the supporting blood vessels.

Regulation of insulin release thus requires the interjection of a number of signals coming from surrounding cells in the pancreatic islet, the blood and nerve endings. Failure to coordinate these signals in a right way may be an explanation for why beta cells of diabetic patients fail to release enough insulin.

Over the past years, new insights into differences between human and mouse islets have shaken the diabetes research field. Mouse islets have been commonly used as a model to study the molecular processes and how they can be influenced to treat a diabetic patient. Now, Prof Berggren’s group focuses on defining the differences between mouse and human islets to make targeted and accurate treatment strategies applicable in man.

To study how insulin release is regulated from the pancreatic beta-cell in the context of the whole body, Prof Berggren’s group has developed InSight Technology: The islets are transplanted into the anterior chamber of the eye, where they are established, get blood supply and nerve connections, and function as they do in the pancreas. The technology gives a unique possibility to image the important molecular processes previously studied in beta cells separated from their natural environment. InSight is also vital for defining novel pharmacological strategies for the treatment of diabetes.

The results are summarized in the article published in September 2012: The pancreatic islet as a signaling hub. Barker CJ, Leibiger IB, Berggren PO. Advances in Biological Regulation. 2012 Sept 28.

October 31, 2013 Catharina Rahm

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Categories

Recent posts

  • Professor Berggren’s research publications
    Professor Berggren’s research publications February 6, 2025
  • Årsstämma 17 juni 2024
    Årsstämma 17 juni 2024 June 2, 2024
  • Researchers use the eye as a window to study liver health
    Researchers use the eye as a window to study liver health February 8, 2024
  • ERC Proof of Concept to Professor Per-Olof Berggren
    ERC Proof of Concept to Professor Per-Olof Berggren February 7, 2024
  • The anterior chamber of the eye as a servant to medical research in translation
    The anterior chamber of the eye as a servant to medical research in translation February 7, 2024
  • Lisa Juntti-Berggren receives the Swedish Society of Medicine’s Jubilee Prize
    Lisa Juntti-Berggren receives the Swedish Society of Medicine’s Jubilee Prize February 7, 2024
  • Eye implant may be used to treat diabetes
    Eye implant may be used to treat diabetes February 7, 2024
  • Årsstämma 16 juni 2023
    Årsstämma 16 juni 2023 May 29, 2023
  • New strategy to preserve insulin-producing cells in diabetes
    New strategy to preserve insulin-producing cells in diabetes August 19, 2022
  • Kallelse till årsstämma 27 juni 2022
    Kallelse till årsstämma 27 juni 2022 June 6, 2022

Biocrine AB

Box 3073

169 03 Solna, Sweden

Contact Us

info at biocrine.se

www.biocrine.com

Copyright © 2012 Biocrine AB. All Rights Reserved